Cholestech (CTEC) Receives FDA CLIA Waived Status for New Combined Test Panel
Cholestech Corporation (Nasdaq: CTEC) announces that the FDA has granted CLIA waived status to the Company's newest test panel, Lipid Profile ALT. The new test panel, designed for use with the Cholestech LDX® System, combines an ALT test with a lipid profile, providing total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride and alanine aminotransferase (ALT) results from a single fingerstick.
By testing at the point of care, the Lipid Profile ALT test allows physicians in the US to immediately assess elevated cholesterol levels and liver damage at the same time allowing for medication dosage adjustments and safety monitoring on-the-spot.
By testing at the point of care, the Lipid Profile ALT test allows physicians in the US to immediately assess elevated cholesterol levels and liver damage at the same time allowing for medication dosage adjustments and safety monitoring on-the-spot.
You May Also Be Interested In
- Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
- Amgen (AMGN) Updates on Exploratory Biomarker Analysis for AMG 102 Response Predictor
- Amgen (AMGN) Says AMG 103 Achieves High-Rate of CR in B-Precursor ALL Following Phase 2 Data
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
